Document:

Exhibit
      10.1

    

    

    July
      27,
      2007

     

    Thane
      Kreiner

    c/o
      Affymetrix, Inc.

    3420
      Central Expressway

    Santa
      Clara, CA 95051

    

    Dear
      Thane:

     

    This
      letter agreement (the “Agreement”) sets forth our mutual
      agreement with respect to your separation from employment with Affymetrix,
      Inc.
      (the “Company”).

     

    1.        Separation
      Date.  Effective July 27, 2007 (the “Separation
      Date”), your employment with the Company (including any position you
      hold with any of the Company’s subsidiaries) has terminated.

     

    2.        Separation
      Benefits.  Subject to your signing and letting become effective
      the release set forth in Section 3 below and continued compliance with the
      covenants set forth in the Confidentiality Agreement (as defined below) and
      Section 4 of this Agreement, you will receive the following:

     

    (a)                 An
      amount equal to (i) $362,308, representing the salary you would have received
      through October 20, 2008, plus (ii) $117,000, representing a portion of your
      annual target bonus, each of which shall be paid in six equal installments
      over
      the six-month period following the Separation Date.  The first payment
      shall be made within ten days following the execution this
      Agreement.

     

    (b)                 To
      the extent you elect health coverage pursuant to COBRA, Company reimbursement
      of
      your COBRA premiums through the earlier of (i) October 20, 2008 or (ii) the
      date
      on which you become eligible for group coverage with another
      employer.

     

    (c)                 Accelerated
      vesting of your stock options and restricted stock to the extent they would
      have
      vested if you had remained employed through October 20, 2008.  Your
      vested stock options shall remain exercisable until the earlier of
      (i) January 20, 2009 (ii) the maximum term set forth in the applicable
      stock option or restricted stock agreements or (iii) termination of all
      stock options and or restricted stock in accordance with the terms of the
      applicable stock plans; provided that you understand that any stock
      options with an exercise period longer than three months following the
      Separation Date shall not be considered “incentive stock options”.

     

    (d)                 The
      Company will pay for up to 12 months of a job placement service in an aggregate
      amount not to exceed $20,000.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (e)                 The
      Company will pay for reasonable legal counsel fees incurred by you in connection
      with the execution of this Agreement.  You will provide the Company
      with reasonable evidence of such fees in the form of a summary bill prior to
      receiving reimbursement.  The amount reimbursed by the Company
      pursuant to this clause (e) will not exceed $50,000.

     

    Notwithstanding
      anything in this Agreement to the contrary, to the extent that the Company
      determines in good faith that any payment provided for in this Agreement
      constitutes a “deferral of compensation” under Section 409A of the Internal
      Revenue Code, then such payment shall not be paid prior to the earlier of:
      (i) the date that is six months following the Separation Date or
      (ii) your death.

     

    3.        Release.

     

    (a)                 You
      acknowledge that the following releases shall extend to unknown, as well as
      known claims, and hereby waive the application of any provision of law,
      including, without limitation, Section 1542 of the California Civil Code,
      that purports to limit the scope of a general
      release.  Section 1542 of the California Civil Code
      provides:

     

    “A
      GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW
      OR
      SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF
      KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE
      DEBTOR.”

     

    (b)                 You
      agree to and do fully and completely release, discharge and waive any and all
      claims, complaints, causes of action or demands of whatever kind which you
      have
      or may have against the Company, its subsidiaries, affiliates, predecessors
      and
      successors and all its directors, officers, employees, stockholders and other
      investors by reason of any event, matter, cause or thing which has occurred
      prior to the date hereof (“Executive Claims”).  You
      understand and accept that this release specifically covers, but is not limited
      to, any and all Executive Claims relating in any way to compensation, to any
      previous agreements between you and the Company related to your employment,
      or
      to any other terms, conditions or circumstances of your employment with the
      Company or the termination thereof, whether for severance or based on statutory
      or common law claims for employment discrimination (including discrimination
      on
      the basis of sex, age, religion or disability, including specifically any claims
      under the Age Discrimination in Employment Act (the “ADEA”),
      Title VII of the Civil Rights Act of 1964, as amended, or the Americans with
      Disabilities Act of 1990), wrongful discharge, breach of contract or any other
      theory, whether legal or equitable.  Notwithstanding the foregoing,
      you do not waive any rights to which you may be entitled to seek to enforce
      this
      Agreement, or to seek indemnification with respect to liability incurred by
      you
      as an employee, officer or director of the Company in accordance with the
      Company’s bylaws and any indemnification agreement between you and the Company
      (the “Indemnification Agreement”).

     

    (c)                 Acknowledgement
      of Waiver of Claims Under ADEA.  You acknowledge that you are
      waiving and releasing any rights you may have under the ADEA and that
      this

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    waiver
      and
      release is knowing and voluntary.  You and the Company agree that this
      waiver and release does not apply to any rights or claims that may arise under
      ADEA after the Separation Date.  You acknowledge that the
      consideration given for this waiver and release is in addition to anything
      of
      value to which you were already entitled.  You further acknowledge
      that you have been advised by this writing that:

     

    (i)              You
      should consult with an attorney prior to executing this
      Agreement.

     

    (ii)              You
      have up to 21 days within which to consider this Agreement.

     

    (iii)              You
      have seven days following your execution of this Agreement to revoke the release
      set forth in this Section, in which case the Company shall have no obligations
      to you under this Agreement.

     

    4.        Restrictive
      Covenants.

     

    (a)                 Confidentiality
      Agreement.  Your obligations under your existing Confidentiality
      and Invention Agreement with the Company (the “Confidentiality
      Agreement”) remain in effect after the effective date of this
      Agreement.

     

    (b)                 Non-Solicitation.  Without
      limiting the foregoing, you agree that through the date that is 12 months
      following the Separation Date: (i) you will not directly or indirectly
      solicit any employee of the Company or any of its affiliates to terminate his
      or
      her employment with the Company or any of its affiliates; and (ii) you will
      not directly or indirectly solicit customers or suppliers of the Company based
      on confidential information of the Company or solicit any such person to
      terminate his, her or its relationships with the Company.

     

    (c)                 No
      Disparagement.  During and after your employment with the
      Company, you agree that you shall not make negative statements or
      representations, or otherwise communicate negatively, directly or indirectly,
      in
      writing, orally, or otherwise, or take any action which may, directly or
      indirectly, disparage or be damaging to the Company, its subsidiaries,
      affiliates, successors or their officers, directors, employees, business or
      reputation, except as may be required by law or by any regulatory
      authority.  The Company agrees that neither it nor its officers and
      directors shall make any negative statements or representations, or otherwise
      communicate negatively, directly or indirectly, in writing, orally or otherwise,
      or take any action which may, directly or indirectly, disparage or be damaging
      to you or your reputation.

     

    (d)                 Employment.  As
      specific consideration for a portion of the severance payments and benefits
      provided under Section 2 of this Agreement, you agree not to work for either
      Agilent or Illumina (or their affiliates or successors) for a period of 12
      months after the Separation Date.  In the event of your breach of this
      clause (d), the Company shall have the right to cease any payments and benefits
      being provided to you pursuant to Section 1 of this Agreement.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    (e)                 Remedies.  You
      and the Company acknowledge and agree that the Parties’ remedies at law for a
      breach or threatened breach of any of the provisions of this Section would
      be
      inadequate and, in recognition of this fact, you agree that, in the event of
      a
      breach or threatened breach, in addition to any remedies at law, the Parties,
      without posting any bond, shall be entitled to obtain equitable relief in the
      form of specific performance, temporary restraining order, temporary or
      permanent injunction or any other equitable remedy which may then be
      available.

     

    5.        Entire
      Agreement; Amendment.  Except as expressly set forth herein, and
      except for your stock option agreements (as amended hereby), the Confidentiality
      Agreement and the Indemnification Agreement, this Agreement shall supersede
      any
      and all existing agreements between you and the Company or any of its affiliates
      relating to the terms of your employment and contains the entire understanding
      of the parties with respect to your employment and the termination
      thereof.  This Agreement may not be altered, modified or amended
      except by a written agreement signed by both parties hereto.

     

    6.        No
      Waiver.  The failure of a party to insist upon strict adherence
      to any term of this Agreement on any occasion shall not be considered a waiver
      of such party’s rights or deprive such party of the right thereafter to insist
      upon strict adherence to that term or any other term of this
      Agreement.

     

    7.        Severability.  In
      the event that any one or more of the provisions of this Agreement shall be
      or
      become invalid, illegal or unenforceable in any respect, the validity, legality
      or enforceability of the remaining provisions of this Agreement shall not be
      affected thereby.

     

    8.        Assignment.  This
      Agreement shall inure to the benefit of and be binding upon the parties hereto
      and their respective heirs, representatives, successors and
      assigns.  This Agreement shall not be assignable by you and shall be
      assignable by the Company only to an affiliate or successor thereof, which
      affiliate or successor shall assume all of the Company’s obligations to you
      hereunder.

     

    9.        Acknowledgement.  You
      acknowledge that you have carefully read this Agreement, fully understand and
      accept all of its provisions and sign it voluntarily of your own free
      will.

     

    10.      Withholding.  You
      agree that any payments to which you may be entitled pursuant to this Agreement
      are subject to withholding by the Company of any applicable federal, state
      or
      local taxes; provided that you understand that you remain ultimately
      responsible for any tax consequences hereunder.

     

    11.      Governing
      Law.  This Agreement shall be governed by and construed in
      accordance with the laws of the State of California, without regard for the
      conflicts of law principles thereof.

     

    12.      Arbitration.

     

    (a)                 
      Any dispute or controversy arising out of, relating to, or in connection with
      this Agreement, or the interpretation, validity, construction, performance,
      breach, or termination thereof, shall be settled by binding and confidential
      arbitration to be held in Santa Clara County, California, in accordance with
      the
      National Rules for the Resolution of Employment Disputes then

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    in
      effect
      of the American Arbitration Association (the
“Rules”).  The arbitrator may grant injunctions or
      other relief in such dispute or controversy.  The decision of the
      arbitrator shall be final, conclusive and binding on the parties to the
      arbitration.  Judgment may be entered on the arbitrator's decision in
      any court having jurisdiction.

     

    (b)                 The
      arbitrator(s) shall apply California law to the merits of any dispute or claim,
      without reference to conflicts of law rules.  The arbitration
      proceedings shall be governed by federal arbitration law and by the Rules,
      without reference to state arbitration law.  You hereby consent to the
      personal jurisdiction of the state and federal courts located in California
      for
      any action or proceeding arising from or relating to this Agreement or relating
      to any arbitration in which the parties are participants.

     

    (c)           The
      Company and you shall each pay one-half of the costs and expenses of the
      arbitration, and each party shall bear its own respective attorneys’ fees and
      all other costs, unless otherwise required or allowed by law and awarded by
      the
      arbitrator.

     

    13.                   Notices.
      Except as otherwise explicitly provided in this Agreement, any notice provided
      hereunder will be deemed to be given when delivered in writing by hand, by
      facsimile or sent by overnight courier.  All notices to the Company
      will be marked confidential and addressed to the Company’s General
      Counsel.  All notices to you will be addressed to your most recent
      address as reflected on the Company’s payroll and sent to such other address as
      you may provide from time to time by notice to the Company, or any other
      persons or
      addresses as you may request from time to time by notice to the
      Company.

     

    14.                   Counterparts.  This
      Agreement may be signed in counterparts, each of which shall be an original,
      with the same effect as if the signatures thereto and hereto were upon the
      same
      instrument.

     

     

     

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    Please
      acknowledge your acceptance of the foregoing by signing where indicated
      below.

     

    
      	 	
              AFFYMETRIX,
                INC.

            	 
	 	 	 	 
	 	 	 	 
	 	
              By:

            	
              /s/
                Barbara A. Caulfield

            	 
	 	
              Name:
                Barbara A. Caulfield

            	 
	 	
              Title:   
                EVP and General Counsel

            	 

    

    

    Accepted
      and Agreed:

     

    /s/
      Thane Kreiner

    Thane
      Kreiner

     

    July
      27, 2007

    DateEX-4.1

 

Exhibit 4.1

[FORM OF WARRANT]

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES
INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH
COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT
REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A
UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A
BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

ELECTRO-OPTICAL SCIENCES, INC.

Warrant To Purchase Common Stock

Warrant No.:                     

Number of Shares of Common Stock:                    

Date of Issuance: August    , 2007 (“Issuance Date”)

     Electro-Optical Sciences, Inc., a corporation organized under the laws of Delaware (the
“Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, [BUYERS], the registered holder hereof or its permitted assigns
(the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at
the Exercise Price (as defined below) then in effect, upon surrender of this Warrant to Purchase
Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or
replacement hereof, the “Warrant”), at any time or times on or after one hundred and eighty days
(180) from the date hereof, but not after 11:59 p.m., New York time, on the Expiration Date (as
defined below), ___(___)1 fully paid nonassessable shares of
Common Stock (as defined below) (the “Warrant Shares”). Except as otherwise defined herein,
capitalized terms in this Warrant shall have the meanings set forth in Section 16. This Warrant is
one of the Warrants to purchase Common Stock (the “SPA Warrants”) issued pursuant to Section 1 of
that certain Securities Purchase Agreement, dated as of July 31, 2007 (the “Subscription Date”), by
and among the Company and the investors (the “Buyers”) referred to therein (the “Securities
Purchase Agreement”).

 

			
	1	 	Insert number of shares equal to 25% of the
number of Common Stock purchased under the Securities Purchase Agreement
rounded down to the nearest whole number.

  

 

     1. EXERCISE OF WARRANT.

          (a) Mechanics of Exercise. Subject to the terms and conditions hereof (including,
without limitation, the limitations set forth in Section 1(f)), this Warrant may be exercised by
the Holder on any day on or after one hundred and eighty days (180) from the date hereof to and
including the Expiration Date, in whole or in part, by (i) delivery of a written notice, in the
form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s election to
exercise this Warrant and (ii) (A) payment to the Company of an amount equal to the applicable
Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being
exercised (the “Aggregate Exercise Price”) in cash or by wire transfer of immediately available
funds or (B) by notifying the Company that this Warrant is being exercised pursuant to a Cashless
Exercise (as defined in Section 1(d)). At 11:59 P.M., New York City time on the Expiration Date,
the portion of this Warrant not exercised prior thereto shall be and become void and of no value.
The Holder shall not be required to deliver the original Warrant in order to effect an exercise
hereunder. Execution and delivery of the Exercise Notice with respect to less than all of the
Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a
new Warrant evidencing the right to purchase the remaining number of Warrant Shares. On or before
the second (2nd) Business Day following the date on which the Company has received each of the
Exercise Notice and the Aggregate Exercise Price (or notice of a Cashless Exercise) (the “Exercise
Delivery Documents”), the Company shall transmit by facsimile an acknowledgment of confirmation of
receipt of the Exercise Delivery Documents to the Holder and the Company’s transfer agent (the
“Transfer Agent”). On or before the third (3rd) Business Day following the date on
which the Company has received all of the Exercise Delivery Documents (the “Share Delivery Date”),
the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust
Company (“DTC”) Fast Automated Securities Transfer Program and the Warrant Shares may be issued
without any restrictive legends in accordance with Section 2(g) of the Securities Purchase
Agreement, upon the request of the Holder, credit such aggregate number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account
with DTC through its Deposit Withdrawal Agent Commission system, or (Y) if the Transfer Agent is
not participating in the DTC Fast Automated Securities Transfer Program, issue and dispatch by
overnight courier to the address as specified in the Exercise Notice, a certificate, registered in
the Company’s share register in the name of the Holder or its designee, for the number of shares of
Common Stock to which the Holder is entitled pursuant to such exercise, which certificate shall
bear any legends required in accordance with Section 2(g) of the Securities Purchase Agreement.
Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the
Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as
the case may be. If this Warrant is submitted in connection with any exercise pursuant to this
Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is
greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall
as soon as practicable issue a new Warrant (in accordance with Section 7(d)) representing the right
to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this
Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. No
fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather
the number of shares of Common Stock to be issued shall be rounded

 - 2 - 

 

up to the nearest whole number. The Company shall pay any and all taxes which may be payable
with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant.

          (b) Exercise Price. For purposes of this Warrant, “Exercise Price” means $8.00,
subject to adjustment as provided herein.

          (c) Company’s Failure to Timely Deliver Securities. If the Company shall fail for any
reason or for no reason to issue to the Holder within three (3) Business Days of receipt of the
Exercise Delivery Documents, a certificate for the number of shares of Common Stock to which the
Holder is entitled and register such shares of Common Stock on the Company’s share register or to
credit the Holder’s balance account with DTC for such number of shares of Common Stock to which the
Holder is entitled upon the Holder’s exercise of this Warrant or if the Company fails to deliver to
the Holder a certificate or certificates representing the applicable Warrant Shares within three
(3) Trading Days after its obligation to do so under clause (ii) below, and if on or after such
Trading Day the Holder purchases (in an open market transaction or otherwise) shares of Common
Stock to deliver in satisfaction of a sale by the Holder of shares of Common Stock issuable upon
such exercise or receipt that the Holder anticipated receiving from the Company (a “Buy-In”), then
the Company shall, within three (3) Business Days after the Holder’s request and in the Holder’s
discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase
price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the
“Buy-In Price”), at which point the Company’s obligation to deliver such certificate (and to issue
such Warrant Shares) shall terminate, or (ii) promptly honor its obligation to deliver to the
Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in
an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of
shares of Common Stock, times (B) the Closing Bid Price on the date of exercise.

          (d) Cashless Exercise. Notwithstanding anything contained herein to the contrary, if
a Registration Statement (as defined in the Registration Rights Agreement) covering the Warrant
Shares that are the subject of the Exercise Notice (the “Unavailable Warrant Shares”) is not
available for the resale of such Unavailable Warrant Shares, the Holder may, in its sole
discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment
otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate
Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common
Stock determined according to the following formula (a “Cashless Exercise”):

	 	 	 	 	 	 	 
	Net Number

	 	=
	 	(A x B) - (A x C)
	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	B	 	 

          For purposes of the foregoing formula:

	     A =	 	 the total number of shares with respect to which
this Warrant is then being exercised.

 - 3 - 

 

	 	B =	 	 the Closing Sale Price of the shares of Common
Stock (as reported by Bloomberg) on the date immediately preceding
the date of the Exercise Notice.
	 
	 	C =	 	the Exercise Price then in effect for
the applicable Warrant Shares at the time of such
exercise.

          (e) Limitations on Exercises; Beneficial Ownership. The Company shall not effect the
exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant, to the
extent that after giving effect to such exercise, such Holder (together with such Holder’s
affiliates, and any other Persons whose beneficial ownership of Common Stock would be aggregated
with such Holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)) would beneficially own in excess of 4.99% of the shares of Common Stock
outstanding immediately after giving effect to such exercise. For purposes of the foregoing
sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its
affiliates shall include the number of shares of Common Stock issuable upon exercise of this
Warrant with respect to which the determination of such sentence is being made, but shall exclude
shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised
portion of this Warrant beneficially owned by such Holder and its affiliates and (ii) exercise or
conversion of the unexercised or unconverted portion of any other securities of the Company
beneficially owned by such Person and its affiliates (including, without limitation, any
convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion
or exercise analogous to the limitation contained herein. Except as set forth in the preceding
sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance
with Section 13(d) of the Securities Exchange Act of 1934, as amended. For purposes of this
Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on
the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Form
10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange
Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any
other notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding. For any reason at any time, upon the written or oral request of the Holder, the
Company shall within two (2) Business Days confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of
Common Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including the SPA Warrants, by the Holder and its affiliates since the date as of
which such number of outstanding shares of Common Stock was reported. By written notice to the
Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other
percentage not in excess of 9.99% specified in such notice; provided that (i) any such increase
will not be effective until the sixty-first (61st) day after such notice is delivered to
the Company, and (ii) any such increase or decrease will apply only to the Holder and not to any
other holder of SPA Warrants.

          (f) Insufficient Authorized Shares. If at any time while any of the Warrants remain
outstanding the Company does not have a sufficient number of authorized and unreserved shares of
Common Stock to satisfy its obligation to reserve for issuance upon exercise of the Warrants at
least a number of shares of Common Stock equal to 100% (the

 - 4 - 

 

“Required Reserve Amount”) of the number of shares of Common Stock as shall from time to time
be necessary to effect the exercise of all of the Warrants then outstanding, then the Company shall
immediately take all action necessary to increase the Company’s authorized shares of Common Stock
to an amount sufficient to allow the Company to reserve the Required Reserve Amount for the
Warrants then outstanding.

     2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. If the Company, at any
time while this Warrant is outstanding, subdivides (by any stock split, stock dividend,
recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a
greater number of shares, the Exercise Price in effect immediately prior to such subdivision will
be proportionately reduced and the number of Warrant Shares will be proportionately increased. If
the Company, at any time while this Warrant is outstanding, combines (by combination, reverse stock
split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller
number of shares, the Exercise Price in effect immediately prior to such combination will be
proportionately increased and the number of Warrant Shares will be proportionately decreased. Any
adjustment under this Section 2 shall become effective at the close of business on the date the
subdivision or combination becomes effective.

     3. RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares
of Common Stock (which dividend or other distribution has not already been given to the Holders of
the Warrants), by way of return of capital or otherwise (including, without limitation, any
distribution of cash, stock or other securities, property or options by way of a dividend, spin
off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a “Distribution”), at any time after the issuance of this Warrant and prior to the Expiration
Date, then, in each such case:

          (a) any Exercise Price in effect immediately prior to the close of business on the record date
fixed for the determination of holders of shares of Common Stock entitled to receive the
Distribution shall be reduced, effective as of the close of business on such record date, to a
price determined by multiplying such Exercise Price by a fraction of which (i) the numerator shall
be the Closing Bid Price of the shares of Common Stock on the Trading Day immediately preceding
such record date minus the value of the Distribution (as determined in good faith by the Company’s
Board of Directors) applicable to one share of shares of Common Stock, and (ii) the denominator
shall be the Closing Bid Price of the shares of Common Stock on the Trading Day immediately
preceding such record date; and

          (b) the number of Warrant Shares shall be increased to a number of shares equal to the number
of shares of Common Stock obtainable immediately prior to the close of business on the record date
fixed for the determination of holders of shares of Common Stock entitled to receive the
Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding
paragraph (a); provided that in the event that the Distribution is of shares of Common Stock (or
common stock) (“Other Shares of Common Stock”) of a company whose common shares are traded on a
national securities exchange or a national automated quotation system, then the Holder may elect to
receive a warrant to purchase Other Shares of Common Stock in lieu of an increase in the number of
Warrant Shares, the terms of which shall

 - 5 - 

 

be identical to those of this Warrant, except that such warrant shall be exercisable into the
number of shares of Other Shares of Common Stock that would have been payable to the Holder
pursuant to the Distribution had the Holder exercised this Warrant immediately prior to such record
date and with an aggregate exercise price equal to the product of the amount by which the exercise
price of this Warrant was decreased with respect to the Distribution pursuant to the terms of the
immediately preceding paragraph (a) and the number of Warrant Shares calculated in accordance with
the first part of this paragraph (b).

     4. FUNDAMENTAL TRANSACTIONS. If, at any time while this Warrant is outstanding there
is a Fundamental Transaction, then the Holder shall have the right thereafter to receive, upon
exercise of this Warrant, the same amount and kind of securities, cash or property as it would have
been entitled to receive upon the occurrence of such Fundamental Transaction if it had been,
immediately prior to such Fundamental Transaction, the Holder of the number of Warrant Shares then
issuable upon exercise in full of this Warrant (the “Alternate Consideration”). For purposes of
any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply
to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the
Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are
given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
receives upon any exercise of this Warrant following such Fundamental Transaction. Any successor
to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new
warrant substantially in the form of this Warrant and consistent with the foregoing provisions and
evidencing the Holder’s right to purchase the Alternate Consideration for the aggregate Exercise
Price upon exercise thereof. The terms of any agreement pursuant to which a Fundamental
Transaction is effected shall include terms requiring any such successor or surviving entity to
comply with the provisions of this paragraph (b) and insuring that the Warrant (or any such
replacement security) will be similarly adjusted upon any subsequent transaction analogous to a
Fundamental Transaction.

     5. NONCIRCUMVENTION. The Company hereby covenants and agrees that the Company will
not, except and to the extent as waived or consented to by the Holder, by amendment of its
Certificate of Incorporation, Bylaws or through any reorganization, transfer of assets,
consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of
this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and
take all action as may be required to protect the rights of the Holder. Without limiting the
generality of the foregoing, the Company (i) shall not increase the par value of any shares of
Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect,
(ii) shall take all such actions as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of
this Warrant, and (iii) shall, so long as any of the SPA Warrants are outstanding, take all action
necessary to reserve and keep available out of its authorized and unissued shares of Common Stock,
solely for the purpose of effecting the exercise of the SPA Warrants, 100% of the number of shares
of Common Stock as shall from time to time be

 - 6 - 

 

necessary to effect the exercise of the SPA Warrants then outstanding (without regard to any
limitations on exercise).

     6. WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided
herein, the Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be
entitled to vote or receive dividends or be deemed the holder of share capital of the Company for
any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder,
solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a shareholder
of the Company or any right to vote, give or withhold consent to any corporate action (whether any
reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or
otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise,
prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to
receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant
shall be construed as imposing any liabilities on the Holder to purchase any securities (upon
exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities
are asserted by the Company or by creditors of the Company. Notwithstanding this Section 6, the
Company shall provide the Holder with copies of the same notices and other information given to the
shareholders of the Company generally, contemporaneously with the giving thereof to the
shareholders.

     7. REISSUANCE OF WARRANTS.

          (a) Transfer of Warrant. If this Warrant is to be transferred, the Holder shall
surrender this Warrant to the Company, together with a written assignment of this Warrant duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes
payable upon the making of such transfer, if any, whereupon the Company will forthwith issue and
deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as
the Holder may request, representing the right to purchase the number of Warrant Shares being
transferred by the Holder and, if less than the total number of Warrant Shares then underlying this
Warrant is being transferred, a new Warrant (in accordance with Section 7(d)) to the Holder
representing the right to purchase the number of Warrant Shares not being transferred.

          (b) Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the
Holder to the Company reasonably satisfactory to the Company and, in the case of mutilation, upon
surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a
new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares
then underlying this Warrant.

          (c) Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the
surrender hereof by the Holder at the principal office of the Company, for a new Warrant or
Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the
number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the
right to purchase such portion of such Warrant Shares as is designated in writing by the Holder at
the time of such surrender; provided, however, that no

 - 7 - 

 

Warrants for fractional shares of Common Stock shall be given.

          (d) Issuance of New Warrants. Whenever the Company is required to issue a new Warrant
pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this
Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase
the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued
pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when
added to the number of shares of Common Stock underlying the other new Warrants issued in
connection with such issuance, does not exceed the number of Warrant Shares then underlying this
Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is
the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

     8. COMPANY OPTIONAL EXERCISE. (a) If at any time following the date the Registration
Statement is declared effective and from and after the two (2) year anniversary of the Issuance
Date (the “Optional Exercise Eligibility Date”), the Closing Sale Price of the Common Stock of the
Company is no less than one hundred fifty percent (150%) of the Exercise Price for any ten (10)
consecutive Trading Days (an “Optional Exercise Measuring Period”) and the Company has not failed
to satisfy all of the Equity Conditions during the period commencing on the Optional Exercise
Notice Date (as defined below) and ending on the Optional Exercise Date (as defined below), the
Company shall have the right to require the Holder to exercise all or any portion of this Warrant
as designated in an Optional Exercise Notice (as defined below), as of the Optional Exercise Date
(as defined below) (an “Optional Exercise”). The Company may exercise its right to require
exercise of this Warrant under this Section 8(a) by delivering a written notice thereof by
facsimile and overnight courier to the Holder and the Transfer Agent (the “Optional Exercise
Notice” and the date all of the holders received such notice is referred to as the “Optional
Exercise Notice Date”) no later than ten (10) Trading Days after the applicable Optional Exercise
Measuring Period. The Optional Exercise Notice delivered shall be irrevocable and shall state (A)
the date on which the Optional Exercise shall occur (the “Optional Exercise Date”) which date shall
be the twentieth (20th) Trading Day after the Optional Exercise Notice Date, and (B) the
aggregate number of Warrant Shares of which the Company has elected to be subject to Optional
Exercise from all of the Buyers pursuant to this Section 8.

          (b) Pro Rata Redemption Requirement. If the Company elects to cause an Optional
Exercise pursuant to Section 8(a), then it must simultaneously take the same action with respect to
the other SPA Warrants. If the Company elects to cause an Optional Exercise pursuant to Section
8(a) (or similar provisions under the other SPA Warrants) with respect to less than all of the
Warrant Shares underlying the SPA Warrants then outstanding, then the Company shall require
exercise of the Warrant Shares from each of the holders of the SPA Warrants equal to the product of
(i) the aggregate number of Warrant Shares which the Company has elected to cause to be exercised
pursuant to Section 8(a), multiplied by (ii) a fraction, the numerator of which is the sum of the
aggregate number of Warrant Shares underlying the SPA Warrants issued to such holder pursuant to
the Securities Purchase Agreement and the denominator of which is the sum of the aggregate number
of Warrant Shares underlying the SPA Warrants issued to all holders pursuant to the Securities
Purchase Agreement (such fraction with respect to each holder is referred to as its “Exercise
Allocation Percentage,” and such amount with respect to each holder is referred to as its “Pro Rata
Exercise Amount”). In the event that

 - 8 - 

 

the initial holder of any SPA Warrants shall sell or otherwise transfer any of such holder’s
SPA Warrants, the transferee shall be allocated a pro rata portion of such holder’s Exercise
Allocation Percentage and Pro Rata Exercise Amount.

     9. NOTICES. Whenever notice is required to be given under this Warrant, unless
otherwise provided herein, such notice shall be given in accordance with Section 9(f) of the
Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice of
all actions taken pursuant to this Warrant, including in reasonable detail a description of such
action and the reason therefore. Without limiting the generality of the foregoing, the Company
will give written notice to the Holder (i) promptly upon any adjustment of the Exercise Price,
setting forth in reasonable detail, the calculation of such adjustment and (ii) at least fifteen
days prior to the date on which the Company closes its books or takes a record (A) with respect to
any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants,
issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants,
securities or other property to holders of shares of Common Stock or (C) for determining rights to
vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case
that such information shall be made known to the public prior to or in conjunction with such notice
being provided to the Holder.

     10. AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this
Warrant may be amended and the Company may take any action herein prohibited, or omit to perform
any act herein required to be performed by it, only if the Company has obtained the written consent
of the Required Holders; provided that no such action may increase the exercise price of any SPA
Warrant or decrease the number of shares or class of stock obtainable upon exercise of any SPA
Warrant without the written consent of the Holder. No such amendment shall be effective to the
extent that it applies to less than all of the holders of the SPA Warrants then outstanding.

     11. GOVERNING LAW. This Warrant shall be governed by and construed and enforced in
accordance with, and all questions concerning the construction, validity, interpretation and
performance of this Warrant shall be governed by, the internal laws of the State of New York,
without giving effect to any choice of law or conflict of law provision or rule (whether of the
State of New York or any other jurisdictions) that would cause the application of the laws of any
jurisdictions other than the State of New York.

     12. CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the
Company and all the Buyers and shall not be construed against any person as the drafter hereof.
The headings of this Warrant are for convenience of reference and shall not form part of, or affect
the interpretation of, this Warrant.

     13. DISPUTE RESOLUTION. In the case of a dispute as to the determination of the
Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the
disputed determinations or arithmetic calculations via facsimile within two Business Days of
receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If
the Holder and the Company are unable to agree upon such determination or calculation of the
Exercise Price or the Warrant Shares within three Business Days of such disputed determination or
arithmetic calculation being submitted to the Holder, then the Company shall, within two

 - 9 - 

 

Business Days submit via facsimile (a) the disputed determination of the Exercise Price to an
independent, reputable investment bank selected by the Company and approved by the Holder or (b)
the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside
accountant. The Company shall cause at its expense the investment bank or the accountant, as the
case may be, to perform the determinations or calculations and notify the Company and the Holder of
the results no later than ten Business Days from the time it receives the disputed determinations
or calculations. Such investment bank’s or accountant’s determination or calculation, as the case
may be, shall be binding upon all parties absent demonstrable error.

     14. REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies
provided in this Warrant shall be cumulative and in addition to all other remedies available under
this Warrant and the other Transaction Documents, at law or in equity (including a decree of
specific performance and/or other injunctive relief), and nothing herein shall limit the right of
the Holder to pursue actual damages for any failure by the Company to comply with the terms of this
Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.
The Company therefore agrees that, in the event of any such breach or threatened breach, the holder
of this Warrant shall be entitled to seek, in addition to all other available remedies, to an
injunction restraining any breach, without the necessity of showing economic loss and without any
bond or other security being required.

     15. TRANSFER. Subject to applicable law, this Warrant may be offered for sale, sold,
transferred or assigned without the consent of the Company, except as may otherwise be required by
Section 2(f) of the Securities Purchase Agreement.

     16. CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have
the following meanings:

          (a) “Bloomberg” means Bloomberg Financial Markets.

          (b) “Business Day” means any day other than Saturday, Sunday or other day on which commercial
banks in The City of New York are authorized or required by law to remain closed.

          (c) “Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the
last closing bid price and last closing trade price, respectively, for such security on the
Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an
extended hours basis and does not designate the closing bid price or the closing trade price, as
the case may be, then the last bid price or last trade price, respectively, of such security prior
to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the
principal securities exchange or trading market for such security, the last closing bid price or
last trade price, respectively, of such security on the principal securities exchange or trading
market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not
apply, the last closing bid price or last trade price, respectively, of such security in the
over-the-counter market on the electronic bulletin board for such security as reported by
Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for

 - 10 - 

 

such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of
any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC (formerly
the National Quotation Bureau, Inc.). If the Closing Bid Price or the Closing Sale Price cannot be
calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price
or the Closing Sale Price, as the case may be, of such security on such date shall be the fair
market value as mutually determined by the Company and the Holder. If the Company and the Holder
are unable to agree upon the fair market value of such security, then such dispute shall be
resolved pursuant to Section 13. All such determinations to be appropriately adjusted for any
stock dividend, stock split, stock combination or other similar transaction during the applicable
calculation period.

          (d) “Common Stock” means (i) the Company’s shares of Common Stock, par value $0.001 per share,
and (ii) any share capital into which such Common Stock shall have been changed or any share
capital resulting from a reclassification of such Common Stock.

          (e) “Convertible Securities” means any stock or securities (other than Options) directly or
indirectly convertible into or exercisable or exchangeable for shares of Common Stock.

          (f) “Dollar”, “US Dollar” and “$” each mean the lawful money of the United States.

          (g) “Eligible Market” means the Principal Market, The New York Stock Exchange, Inc., the
American Stock Exchange, The NASDAQ Global Market or The NASDAQ Global Select Market.

          (h) “Equity Conditions” means each of the following conditions: (i) the Warrant Shares are
either registered for resale pursuant to an effective registration statement naming the Holder as a
selling stockholder thereunder (and the prospectus thereunder is available for use by the Holder as
to all Warrant Shares) or freely transferable without volume restrictions pursuant Rule 144(k)
promulgated under the 1933 Act, as determined by counsel to the Company pursuant to a written
opinion letter addressed and in form and substance reasonably acceptable to the Holder, (ii) the
Company shall have been in material compliance with and shall not have materially breached any
provision, covenant, representation or warranty of any Transaction Document and (iii) the Common
Stock shall at all times be listed or quoted on an Eligible Market.

          (i) “Expiration Date” means the date 60 months from the Closing Date or, if such date falls on
a day other than a Business Day or on which trading does not take place on the Principal Market (a
“Holiday”), the next date that is not a Holiday.

          (j) “Fundamental Transaction” means that the Company shall, directly or indirectly, in one or
more related transactions, (i) consolidate or merge with or into (whether or not the Company is the
surviving corporation) another Person, or (ii) sell, assign, transfer, convey or otherwise dispose
of all or substantially all of the properties or assets of the Company to another Person, or (iii)
allow another Person to make a purchase, tender or exchange offer that is accepted by the holders
of more than the 50% of the outstanding shares of Common

 - 11 - 

 

Stock (not including any shares of Common Stock held by the Person or Persons making or party
to, or associated or affiliated with the Persons making or party to, such purchase, tender or
exchange offer), or (iv) consummate a stock purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of
arrangement) with another Person whereby such other Person acquires more than the 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock held by the other
Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock purchase agreement or other business combination), (v) reorganize,
recapitalize or reclassify its Common Stock, or (vi) any “person” or “group” (as these terms are
used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the
“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of
50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock..

          (k) “Options” means any rights, warrants or options to subscribe for or purchase shares of
Common Stock or Convertible Securities.

          (l) “Person” means an individual, a limited liability company, a partnership, a joint venture,
a corporation, a trust, an unincorporated organization, any other entity and a government or any
department or agency thereof.

          (m) “Principal Market” means The NASDAQ Capital Market.

          (n) “Registration Rights Agreement” means that certain registration rights agreement by and
among the Company and the Buyers.

          (o) “Required Holders” means the holders of the SPA Warrants representing at least a majority
of shares of Common Stock underlying the SPA Warrants then outstanding.

          (p) “Trading Day” means any day on which the Common Stock is traded on the Principal Market,
or, if the Principal Market is not the principal trading market for the Common Stock, then on the
principal securities exchange or securities market on which the Common Stock is then traded;
provided that “Trading Day” shall not include any day on which the Common Stock is scheduled to
trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is
suspended from trading during the final hour of trading on such exchange or market (or if such
exchange or market does not designate in advance the closing time of trading on such exchange or
market, then during the hour ending at 4:00:00 p.m., New York time).

[Signature Page Follows]

 - 12 - 

 

          IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly
executed as of the Issuance Date set out above.

	 	 	 	 	 
	 	ELECTRO-OPTICAL SCIENCES, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

 

 

EXHIBIT A

EXERCISE NOTICE

TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

WARRANT TO PURCHASE COMMON STOCK

ELECTRO-OPTICAL SCIENCES, INC.

     The undersigned holder hereby exercises the right to purchase ___ of the
shares of Common Stock (“Warrant Shares”) of Electro-Optical Sciences, Inc., a corporation
organized under the laws of Delaware (the “Company”), evidenced by the attached Warrant to
Purchase Common Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined
shall have the respective meanings set forth in the Warrant.

     1. Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be
made as:

	 	 	 	 	 
	 

	 	 	 	a “Cash Exercise” with respect to                                          Warrant Shares; and/or
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	a “Cashless Exercise” with respect to                                          Warrant Shares.
	 

	 	 	 	 

     2. Payment of Exercise Price. In the event that the holder has elected a Cash Exercise with
respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder shall pay the
Aggregate Exercise Price in the sum of $                                         to the Company in accordance with the
terms of the Warrant.

     3. Delivery of Warrant Shares. The Company shall deliver to the holder                     Warrant
Shares in accordance with the terms of the Warrant.

Date:                                         ,                    

	 	 	 
	 
	 	 	 
	Name of Registered Holder

	 	 

	 	 	 	 
	 	 
	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
				

 

 

ACKNOWLEDGMENT

     The Company hereby acknowledges this Exercise Notice and hereby directs American Stock
Transfer & Trust Company to issue the above indicated number of shares of Common Stock in
accordance with the Transfer Agent Instructions dated ___, 2007 from the Company and
acknowledged and agreed to by American Stock Transfer & Trust Company.

	 	 	 	 	 
	 	ELECTRO-OPTICAL SCIENCES, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]